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Key Points 
Somatic mutations are detected at high frequency in patients with a monocytosis and 
are associated with significantly reduced survival  
In those without a WHO defined diagnosis, patients with a mutation have both 
laboratory and clinical features indistinguishable from CMML   
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Abstract  
The diagnosis of chronic myelomonocytic leukaemia (CMML) remains centred on 
morphology, meaning the distinction from a reactive monocytosis is challenging.   
Mutational analysis and immunophenotyping have been proposed as potential tools 
for diagnosis however have not been formally assessed in combination.  We aimed 
to investigate the clinical utility of these technologies by performing targeted 
sequencing, in parallel to current gold standard techniques, on consecutive samples 
referred for investigation of monocytosis over a 2-year period (n=283).  Results were 
correlated with the morphological diagnosis and objective outcome measures 
including overall survival (OS) and longitudinal blood counts.   
Somatic mutations were detected in 79% of patients, being invariably identified in 
those with a confirmed diagnosis (99%) though also in 57% of patients with non-
diagnostic BM features.  The OS in non-diagnostic mutated patients was 
indistinguishable from those with CMML (p=0.118) and significantly worse than 
unmutated patients (p=0.0002).  On multivariate analysis age, ASXL1, CBL, 
DNMT3A, NRAS & RUNX1 mutations retained significance.  Furthermore, the 
presence of a mutation was associated with a progressive fall in 
haemoglobin/platelet levels and increasing monocyte counts compared with mutation 
negative patients.  Of note, the immunophenotypic features of non-diagnostic 
mutated patients were comparable to CMML patients and the presence of aberrant 
CD56 was highly specific for detecting a mutation.  
Overall, somatic mutations are detected at high frequency in patients referred with a 
monocytosis irrespective of diagnosis.  In those without a WHO defined diagnosis, 
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the mutation spectrum, immunophenotypic features and OS are indistinguishable 
from CMML patients and these patients should be managed as such.  
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Introduction 
Distinguishing a reactive monocytosis from Chronic Myelomonocytic Leukaemia 
(CMML) is challenging for the haematopathologist.  Using current WHO diagnostic 
criteria, a persistent monocytosis is the hallmark of disease and demonstrating 
clonality is not a definitive requirement1. This leads to a greater risk of mis-diagnoses 
or mis-classification, particularly in patients with prolonged reactive changes.   
More recently alternative techniques, in particular flow cytometry, have provided a 
potential objective tool to identify patients with disease.  Skewing of the distribution 
of monocyte subsets in the PB (>94% M1 monocytes) has been reported to be both 
sensitive and specific for detecting CMML2. In addition, large studies using targeted 
sequencing panels have identified recurrent somatic mutations in >90% of patients 
with CMML3, providing a further potential tool for diagnosis.  The presence of a TET2 
mutation in combination with  a SRSF2 (or ZRSR2) mutation has been shown to be 
highly specific for a myelomonocytic phenotype4 and these along with ASXL1 are the 
most frequently mutated genes within this disease group3. Whilst the 2016 WHO 
diagnostic criteria have stated these mutations can support a diagnosis of CMML, 
there have been no studies directly assessing the use of this technology in a 
diagnostic setting.  The aim of this study was to determine whether mutational 
analysis and flow cytometry can provide confirmatory evidence of disease and 
predict outcome in patients presenting with a monocytosis. 
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Methods 
Patients and Samples 
The research was undertaken within HMDS (Haematological Malignancy Diagnostic 
Service), a fully integrated laboratory that serves a population of ~6 million and is the 
benchmark for haematopathology services within the UK.  All consecutive samples 
(peripheral blood (PB) or bone marrow (BM)) received between July 2014 and July 
2016 IURPSDWLHQWVyo for the investigation of monocytosis were included.  
Patients with a confirmed myeloid diagnosis prior to July 2014 were excluded.  The 
decision to investigate was at the discretion of the referring clinician and the study 
cohort therefore reflects the variety of samples received in a routine laboratory for 
the investigation of a monocytosis.  An absolute monocyte count was determined on 
all PB samples when received in HMDS (see Table.1) using flow cytometry (see 
Flow cytometry methods).  Interestingly this was calculated to be <1x109/L on a 
proportion of samples (11%), however the vast majority were very close to this 
threshold and review of local blood count parameters and clinical details confirmed 
the presence of a PB monocytosis and clinical suspicion of CMML.  This highlights 
the recognised variation in monocyte counts between laboratories and the difficulty 
when applying arbitrary cut-offs as diagnostic criteria.   
A total of 283 patients were referred during this time period (Table.1) of which 121 
and 162 had an initial PB and BM sample respectively (Fig.1).  A confirmed 
diagnosis was only made on those cases with an ultimate BM sample (n=207). All 
samples were processed according to gold standard techniques and dual reported 
by a team of experienced haematopathologists.  Those with a confirmed diagnosis 
were classified in accordance with the WHO 2008 classification.  Those failing to 
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fulfil the morphological and genetic WHO 2008 criteria, as agreed by 2 
haematopathologists ZHUHFODVVLILHGDVµQRQ-GLDJQRVWLF¶ 
All samples were taken with full-informed patient consent for investigation of a 
suspected haematological disorder. This study had local Institutional Review Board 
approval (REC reference-16/NE/0105) and performed in accordance with the 
Declaration of Helsinki.  
 
Flow Cytometry 
All samples for immunophenotypic analysis were processed within 24 hours. 
Numerical studies and assessment of monocytic CD56 expression were performed 
on BM or PB samples following a stain-lyse-wash procedure (FACSLyse, Becton 
Dickinson, supplementary Table S1 and Fig.S1-2). There was strong correlation 
between monocyte CD56 expression in the PB and BM (supplementary Fig.S5) 
enabling analysis to include samples from either source.   
PB &'&'³FODVVLFDO´PRQRF\WLFVXEVHWVWXGLHVZHUHSHUIRrmed on samples 
following NH4Cl lysis of erythrocytes using a lyse-stain-wash procedure. A minimum 
of 105 leucocytes were acquired on a single cytometer (FACSCanto II, Becton 
Dickinson) for all cases. Monocytes were identified using a combination of CD64, 
CD45, and scatter characteristics and analysed by a single operator (MC) for all 
analyses (supplementary Fig.S3-4). 
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DNA Extraction and Targeted Amplicon Sequencing 
In parallel to the above analyses, samples were subjected to targeted high 
throughput sequencing.  Referring clinicians and haematopathologists were blinded 
to the results of this analysis to exclude reporting or treatment bias.   
DNA was extracted from fresh blood or BM mononuclear cells using the QIAamp 
DNA mini kit (QIAGEN, Manchester, UK).  
Targeted gene sequencing of 27 genes recurrently mutated in myeloid malignancies 
was performed on the MiSeq (Illumina, Chesterford, UK).  Panel design, validation 
and variant filtering criteria are included in the supplementary methods and Table 
S2-3.  The mean coverage of identified variants was 1514x (range 52-5605x). 
 
Clinical Follow-up 
All follow-up BM assessments were performed as clinically indicated by the referring 
clinician. These samples were also processed according to gold standard techniques 
and underwent targeted sequencing in parallel as described above.  Any subsequent 
new diagnoses were recorded. 
Survival data was available for all patients and censored on the date of extraction 
(08/08/2017).  Additional clinical information, including serial full blood count data, 
was collected on a sub-cohort of patients (n=182) either directly from the referring 
hospital or through the Haematological Malignancy Research Network (HMRN, 
n=85)5.  
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Statistical Analysis 
Survival curves were produced using the Kaplan Meier method and simple 
differences in survival were assessed with the log rank test. The impact of 
abnormalities on overall survival (OS) and risk of progression were estimated using 
Cox regression; where variable selection was required to arrive at a multivariable 
regression, the lasso was used for variable selection and results were reported for 
the corresponding relaxed lasso model.   
 
Sensitivity, specificity, positive and negative predictive values were calculated using 
2x2 contingency tables. 
 
Comparison between flow cytometric parameters in the main cohort was performed 
using Mann-Whitney U test.  Correlation between CD56 expression, M1 monocytes 
and mutational analysis was performed using both logistic and poisson regression. 
  
The effect of mutations on longitudinal blood counts were assessed using random 
effects models. Four different models were fitted using a full-factorial interaction 
between time and mutation status: (i) a random intercept model; (ii) a random 
intercept and slope model with uncorrelated random effects; (iii) a random intercept 
and slope model with correlated random effects; and (iv) a random intercept and 
slope model with correlated random effects, additionally adjusted for age and sex. 
For each mutation/blood count relationship the best-fitting model was chosen 
according to a likelihood ratio test.  To limit any potential affect from periods of acute 
illness or intensive treatment, blood count trajectory analysis was restricted to those 
with <40 measurements over >100 days.    
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Results 
Somatic mutations are detected at high frequency in patients with a 
monocytosis irrespective of diagnosis 
To define the mutation spectrum in patients referred with a monocytosis, targeted 
sequencing results were analysed for the total cohort and correlated with the final 
diagnosis in those who underwent BM sampling.  Of the total 283 patients, 
mutation was detected in 78% of samples, the spectrum of which is presented in 
Fig.2A (also see Table S4).  Of these patients, 207 underwent BM assessment for a 
definitive diagnosis.  HMDS provides a centralised, integrated haematopathology 
service and all BMs were reviewed independently by 2 haematopathologists 
ensuring consistent and high quality BM reporting for this purpose.   
In those with a confirmed myeloid malignancy (142/207 cases; 69%) a mutation was 
almost invariably detected (140/142; 99% of cases).  Of the 2 mutation negative 
cases, one had a complex karyotype including inv3 (involving MECOM), leaving only 
one case with no demonstrable clonal abnormality.  The significant majority of 
diagnostic cases (80%; 114/142) were classified as CMML.  The remaining samples 
were classified with a spectrum of myeloid malignancies though importantly 11 
patients were diagnosed with acute myeloid leukaemia (AML) (n=11) highlighting the 
importance of a BM assessment in patients referred with a monocytosis. 
Somatic mutations were also detected at a high frequency in non-diagnostic 
samples.  At least 1 mutation was detected in 37/65 patients (57%) with 
indeterminate features.  The spectrum of mutations in this group mirrored those 
detected in the diagnostic group with TET2, SRSF2 and ASXL1 being most 
frequently mutated (Fig.2B).  The most notable differences in the non-diagnostic 
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group were the absence of high risk mutations including TP53, FLT3 and NPM1 as 
well as those associated with specific morphological abnormalities such as SF3B1  
which correlates strongly with the presence of ring sideroblasts6.  The median and 
mean number of mutations was higher in those with a confirmed diagnosis (median-
3, range 0-8; mean-3) versus those without (median-1, range 0-6; mean-2) (Fig.2C).  
However, in patients with a confirmed mutation, the number of mutations did not 
differ significantly between diagnostic and non-diagnostic groups (p=0.62).   
The median variant allele fraction (VAF) for all variants was 39% (range 5.2-100%; 
Supplementary Fig.S6) and there was no difference between the VAF in diagnostic 
and non-diagnostic cases (p=0.33).  In those with an isolated mutation the median 
VAF was also noted to be high at 38.2% (range 6.3-97.1%) with only 2 variants 
having a VAF of <10%.      
Mutations are therefore found at a very high frequency with a high clonal burden in 
patients with a monocytosis, and involve a similar spectrum of genes, irrespective of 
diagnosis. 
 
Overall survival and blood count trajectory correlate strongly with mutation 
profile  
To understand the long-term clinical impact of detecting these mutations, objective 
outcome measures, including OS and longitudinal blood count analysis, were 
assessed in the total cohort and correlated with the final diagnosis.   
The median survival of all patients from the time of first sampling was 35.2 months 
(95% CI 25mths-not reached; Fig3A).  Survival correlated strongly with the number 
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of mutations.  Those without a mutation had a significantly better OS and even the 
presence of a single mutation resulted in a significant reduction in survival (p=0.004; 
Fig3B).  On univariate analysis, age was strongly associated with survival. For 
mutations occurring in >5% of subjects, ASXL1, CBL, DNMT3A, NRAS & RUNX1 
were all strongly associated with survival, as were EZH2 & STAG2 amongst the less 
frequently mutated genes. In order to investigate multivariate significance, all genes 
mutated in >5% subjects were entered into a lasso survival regression. Taking the 
1SE shrinkage parameter, age, ASXL1, CBL, DNMT3A, NRAS & RUNX1 were 
selected by the lasso and retained significance in a relaxed lasso regression 
(Supplementary Table.S5). 
In those patients who proceeded to a BM biopsy, survival correlated with the final 
morphological diagnosis.  Those without a confirmed diagnosis had a significantly 
better OS than those with CMML or another myeloid malignancy.  However, this 
survival benefit was retained only in those without a demonstrable mutation 
(p=0.0002) with mutated patients having a similar survival to CMML patients 
(p=0.118; NS) (Fig.4). 
Longitudinal blood count data was available for 182 patients though restricted to 
those with <40 measurements over >100 days (n=133) to exclude periods of acute 
hospital admissions (due to periods of acute illness/infection) or intensive 
chemotherapy (median follow-up 465 days; range 119-996days).  The presence of a 
mutation was associated with a significantly lower haemoglobin and platelet count 
and a higher monocyte count relative to those without a mutation which persisted 
over time and followed a divergent trajectory (Fig.5).  With respect to individual 
mutations, certain mutations were associated with increasing or declining blood 
count parameters over time (Supplementary Table.S6).  Monocyte counts were 
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found to increase over time in TET2, SRSF2, ASXL1, NRAS or RUNX1 mutated 
subjects relative to non-mutated; similarly, white blood counts increased in ASXL1, 
NRAS & DNMT3A mutated subjects; and platelet levels decreased in ASXL1, CBL 
and RUNX1 mutated subjects relative to non-mutated. 
In those without a confirmed diagnosis, follow-up BM biopsies were received on 11 
patients.  Importantly, of those with a subsequent diagnosis of CMML, all had a 
confirmed mutation on the original sample.  In total 7/37 (19%) non-diagnostic 
mutated patients had a confirmed diagnosis (6 CMML, 1 MDS).  Furthermore, none 
of the mutation negative cases went on to develop CMML, however 2 patients had 
confirmed alternative haematological diagnoses - DLBCL and Rosai Dorfman 
disease.   
These findings confirm that the presence of a mutation has a significant impact on 
outcome with respect to both survival and blood count parameters.  
 
Peripheral Blood mutation profiling is predictive of a bone marrow diagnosis 
PB mutational analysis has been shown to correlate strongly with BM analysis in 
MDS providing a potential alternative to BM sampling.  To determine if this is also 
true in CMML, matched PB and BM samples were analysed.  A total of 121 PB 
samples were received as the initial sample and somatic mutations were detected in 
66% (80/121).  Forty-five patients (45/121) (37%) had a subsequent BM performed 
for diagnosis.  Sequencing failed on 2 of the matched BM samples.  Of the 124 
variants detected in the remaining 43 patients, there was high concordance between 
PB and BM (96%) with only 5 discordant results.  Importantly these were low level 
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variants at the limit of detection for the test or variants detected at areas of poor 
coverage (SRSF2/ASXL1).  All 9 mutation negative cases were fully concordant.   
The presence of a mutation in the PB was highly predictive of diagnosing a myeloid 
malignancy in BM with all but 1 case with a demonstrable mutation having a 
subsequent diagnosis (PPV 0.97, NPV 1.0 (Supplementary Figure.S7)).  Of note, 
none of the mutation negative (n=11) cases had a subsequent confirmed diagnosis. 
 
Immunophenotypic features correlate strongly with the presence of a mutation 
and a subsequent diagnosis 
Flow cytometry has been proposed as a potential diagnostic tool in the investigation 
of patients with a monocytosis.  To determine whether immunophenotyping can 
predict for the presence of a mutation or a BM diagnosis, flow cytometric analysis 
was performed alongside sequencing.  
Firstly, comparison was made between the immunophenotypic features in the BM of 
those patients with a confirmed diagnosis of CMML versus non-diagnostic samples.  
Importantly, non-diagnostic mutated patients had immunophenotypic features 
indistinguishable from CMML with respect to increased CD64+ monocytes, reduced 
CD14 expression and aberrant CD56 expression on monocytes (Fig.6).  This was 
most pronounced with CD56 expression (in either PB or BM) which was found 
almost exclusively in those with a mutation.  With respect to individual mutations, 
aberrant expression of CD56 was strongly associated with TET2 mutations (OR 4.0; 
95%CI 2.4-6.8; p<0.0001).  
 
14 
 
Peripheral blood monocyte subsets and CD56 expression are predictive of a somatic 
mutation 
The presence of >94% classical (M1) monocytes has been shown to be highly 
sensitive and specific for a diagnosis of CMML2.  PB monocyte subset analysis was 
not available on every patient in the main cohort and to analyse the relationship 
between M1 monocytes, CD56 expression and the mutation profile, a separate 
cohort of 135 patients was investigated.  Of these 135 patients, 95 underwent a 
subsequent BM for definitive diagnosis (CMML=28, MDS=23, MPN=9, non-
diagnostic=27, other=8). The presence of aberrant CD56 was again strongly 
associated with the presence of a mutation (OR 43.9; 95%CI 8.9-793.9; p=0.0003).  
This was also noted, to a lesser extent, with having >94% M1 monocytes (OR 3.9; 
95%CI 1.8-8.7; p=0.0007) (supplementary Table.S7).  There was some correlation 
between the presence of CD56 expression and >94% M1 monocytes (r=0.17, 
p=0.039) and combining both produced a stronger effect (OR 8.5; 95%CI 3.9-19.5; 
p<0.00001). Importantly, combining these phenotypic aberrancies did not capture all 
patients with a mutation.  Whilst CD56 was highly specific for the presence of a 
mutation (98%), sensitivity was only 48%.  Similarly, the presence of >94% M1 
monocytes had a specificity of 75% for detecting a mutation though a sensitivity of 
only 56%.  
With respect to a confirmed diagnosis, both CD56 expression (OR 4.9; 95%CI 1.9-
13; p=0.001) and >94% M1 monocytes (OR 4.2; 95%CI 1.7-11.5; p=0.003) were 
associated with a final diagnosis of CMML though importantly four patients with 
CMML had neither of these phenotypic aberrancies.  
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Discussion 
This is the first study to formally examine the use of mutational analysis in the 
investigation of patients presenting with a monocytosis.  This was performed in 
combination with current gold standard techniques, including recently described flow 
cytometric analyses, in a large patient cohort.  By analysing sequential samples 
referred to a regional diagnostic laboratory this study has investigated the typical 
patient population encountered in routine haematology practice.  The use of 
objective outcome measures (longitudinal blood counts and OS) and an unselected 
patient population have minimised bias and ensured the results are applicable in the 
µUHDO-ZRUOG¶VHWWLQJ.  Using a targeted sequencing panel of recurrently mutated 
genes, this study confirms that somatic mutations are not only identified in virtually 
all patients with a morphological diagnosis of CMML, but also in a significant 
proportion of patients with a monocytosis and non-diagnostic features.  It is possible 
that the proportion of non-diagnostic samples with detectable mutations was inflated 
due to referral bias and a high pre-test probability of disease in those undergoing 
testing, however these patients had a mutation spectrum, immunophenotype and 
outcome indistinguishable from CMML.  The presence of a mutation significantly 
impacted on survival irrespective of the final diagnosis. 
 
A number of technical limitations of this study should be highlighted.  Firstly, as these 
were routine samples referred for investigation, a corresponding germline sample 
was not available for analysis.  The absence of reference material means that the 
distinction between germline variants or private single nucleotide polymorphisms 
(SNPs) and somatic variants is challenging.  However, sequencing was limited to 
well documented driver genes and the landscape of mutations in these genes is well 
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established.  Strict filtering criteria were applied (see Supplementary methods) to 
ensure only high confidence variants were included.  Secondly, the sequencing 
analysis used amplicon based library preparation which has recognised limitations 
with respect to PCR errors and false positive results particularly at low VAF.  The 
panel was however internally and externally validated (see supplementary methods) 
and only reproducible variants were included if detected at low VAF or in areas of 
low coverage.  The results are therefore, to the best of our ability, accurate.  In 
future, sequencing deeper should enable more accurate variant calling at low VAF.       
 
The findings of this study will be key to refining future diagnostic algorithms in the 
investigation of patients referred with a monocytosis.  Mutational analysis has been 
incorporated into the recent amendment of the WHO diagnostic criteria which now 
states that the presence of a mutation can support a diagnosis of CMML.  Concerns 
have however been raised regarding the use of mutational analysis in this setting, 
due to reports of frequent somatic mutations in aging healthy individuals7±10.  As a 
result the WHO have stated that the presence of a mutation in either CMML or MDS 
should not be used alone as proof of disease1.  Our study has however shown that 
even in the absence of morphological features, those patients with a mutation had a 
clinical phenotype and genotype indistinguishable from CMML and a comparably 
poor outcome.  Distinguishing features were also noted between the variants 
reported in healthy individuals and the mutations detected in our study group.  The 
VAF or clone size of the mutations in our study were significantly higher than in 
healthy individuals (median 39.2% vs 9-10%), and this was demonstrated across 
both diagnostic and non-diagnostic samples.  This finding has also been described in 
patients with unexplained cytopenias and several studies have shown that a VAF 
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>10% and the presence of co-occurring mutations can distinguish clinically 
significant cytopenias from healthy individuals11±13.  While the higher VAF is 
replicated in our patient group, importantly our study has shown that even isolated 
mutations have a significant impact on survival in patients with a monocytosis.  
These findings provide strong evidence that in those without diagnostic 
morphological features the presence of a mutation, irrespective of mutation number, 
could be disease defining.  At the very minimum, it is imperative that these patients 
are identified and monitored closely.     
 
It has become increasingly feasible to perform mutational analysis in routine clinical 
practice and this study has demonstrated how modest sized gene panels can 
provide significant diagnostic and prognostic information.  The panel used in the 
study targeted genes implicated in myeloid malignancies and was incorporated into 
the routine workload and performed in µreal time¶ in a cost-effective manner.  The 
genetic profile in CMML is now well established and is noted to be relatively 
homogeneous involving only a restricted number of genes.  Mutation frequencies of 
>90% of patients have been consistently reported using varying panel sizes ranging 
from as few as 19 genes3,14±16.  The mutation profile in our cohort mirrored that 
reported in the literature and despite the restricted panel, the mutation frequency 
was high and a significant impact on outcome was demonstrated.  The recognised 
poor prognostic impact of ASXL1 mutations3,14,17±20, was also replicated across this 
dataset.  Mutational analysis is therefore viable in a routine diagnostic laboratory.  It 
is also likely that a proportion of these patients will have additional mutations in 
genes not sequenced in this study.   To further investigate this would require more 
extensive sequencing on much larger patient populations.   
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The potential for PB to be used as a screening tool for monocytosis has also been 
addressed in this study.  This is an attractive option, particularly in a disease 
commonly presenting in the older patient population.  Using flow cytometry, the 
presence of >94% M1 monocytes in the PB was reported to be both highly sensitive 
and specific for CMML2.  Subsequent studies have validated these findings and also 
confirmed the ability to distinguish CMML from both MDS and MPN cases presenting 
with a monocytosis21,22.  These studies however are centred on morphological 
diagnoses and have not consistently performed mutational analysis.  While our study 
has shown a strong correlation between skewed monocyte subsets and a diagnosis 
of CMML this did not capture all patients and was neither sensitive nor specific for 
the presence of a mutation.  In contrast aberrant CD56 expression was highly 
specific for the presence of a mutation (98%), particularly involving TET2.  CD56 
expression has previously been reported to be highly sensitive and specific for a 
CMML diagnosis (100% and 67% respectively) when combined with other 
immunophenotypic features including reduced expression of myeloid antigens and 
20% immature monocytes23. Subsequent studies however raised concerns 
regarding the overexpression of CD56 in reactive conditions24.  Our data show that 
CD56 expression at diagnosis is invariably associated with the presence of a 
somatic mutation though sensitivity was low (48%).  Flow cytometry could, therefore, 
provide a screening tool for the investigation of PB monocytes but, ultimately, 
mutational analysis will be required to identify patients who require clinical follow-up. 
Importantly there was high concordance between PB and BM mutational analysis 
and the presence of a PB mutation was highly predictive of a subsequent BM 
diagnosis. This suggests that screening of the PB may be a suitable method for 
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identifying or excluding significant mutations, however this could lead to a rise in 
inappropriate referrals and a significant burden on laboratory workload.  
Furthermore, the small proportion of mutated patients in our cohort with other 
haematological malignancies in the BM, including AML, highlights the importance of 
a baseline BM assessment to definitively classify the disease.  In contrast the 
negative predictive value of PB screening was 100% suggesting that those without a 
mutation should not undergo BM assessment.  In the first instance, PB screening 
would be a practical option in those patients unfit for BM assessment or potentially to 
monitor for treatment response or disease evolution.  The latter would require further 
investigation in a prospective study.  
  
In conclusion, this study has confirmed that mutations are commonly detected in 
patients referred with a persistent monocytosis.  The presence of a mutation impacts 
significantly on outcome irrespective of diagnosis, and patients with a mutation who 
fail to meet WHO criteria have CMML disease characteristics.  These findings 
validate the inclusion of somatic mutations in the diagnostic criteria for CMML and at 
the very minimum those without a confirmed diagnosis require close clinical follow-
up.  While PB can be confidently used to detect mutations, a baseline BM biopsy is 
required for definitive disease classification in patients fit for treatment.  
Immunophenotypic assessment of monocytes may provide a potential screening tool 
to detect those with a mutation however it will miss a proportion of mutated patients.  
Ultimately, early identification of patients could provide an opportunity for intervention 
in this patient group and this requires further investigation.   
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Figure Legends 
 
Figure 1. Summary of samples included in study. Flowchart of cases referred for 
investigation of a monocytosis to HMDS.  
*Decision to investigate was at the discretion of the referring clinician 
Focal area of Diffuse Large B-cell Lymphoma noted in bone marrow, likely co-
occurring with CMML 
 
Figure 2. Characteristics of mutations detected in patient samples. (A) 
Spectrum of mutations detected across all patients in study (n=283) 
(B) Comparison of mutations detected in those with a diagnostic bone marrow 
sample vs a non-diagnostic bone marrow sample (diagnostic (n=142) vs non-
diagnostic (n=65)) 
&'LVWULEXWLRQRIQRRIPXWDWLRQVDFFRUGLQJWRILQDOGLDJQRVWLFFDWHJRU\µ2WKHU¶
denotes those patients with an alternative haematological malignancy. 
 
Figure 3. Overall survival according to mutation number. (A) Overall survival in 
total cohort from time of initial sample 
(B) Overall survival in total cohort by no. of mutations detected at time of initial 
sample.  The p-value represents a log rank test comparing those without a mutation 
to those with a single mutation.  
(C) Overall survival in total cohort by the presence or absence of a mutation 
 
Figure 4. Overall survival according to final diagnosis. (A) Overall survival by 
diagnosis on bone marrow sample (n=207) 
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(B) Overall survival by diagnosis with non-diagnostic samples separated by the 
presence or absence of a mutation.  The p-values refer to log-rank tests comparing 
CMML and non-diagnostic unmutated patients (p=0.0002) and comparing CMML 
with non-diagnostic mutated patients (p=0.118) 
 
Figure 5.  Longitudinal blood count trajectories in relation to mutation status. 
Plots of all blood count trajectories averaged between mutated (red) and unmutated 
(black) groups with overlaid linear regression line. 
(A) Haemoglobin (g/L) in patients with or without a detectable mutation.  (B) Platelet 
count (log transformed) in patients with or without a detectable mutation.  (C) 
Monocyte count (log transformed) in patients with or without a detectable mutation.    
 
Figure 6.  Relationship between immunophenotype and mutations. Box and 
whisker plots comparing immunophenotypic features of CMML, non-diagnostic 
mutated (NDM) and non-diagnostic unmutated (NDU) cases.  The p-values refer to 
Mann-Whitney U tests comparing CMML with either non-diagnostic category. 
(A) % CD56 expression on monocytes.  (B) % CD64+ monocytes of leucocytes 
(C) % CD14 expressing monocytes 
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Table 1. Patient Characteristics  
No. of patients 283 
Male:Female 174:109 
Median Age (range) 76 (24-96) 
  
Final Diagnosis 
 
 
PB only 76 
 
CMML 114 
 
AML 11 
 
MPN 9 
 
MDS 4 
 
Other 4 
 
Non-diagnostic 65 
  
 
CMML Other haem 
malignancy 
Non-diagnostic 
    
Median Age (Range) 76 (24-91) 76 (42-93) 73 (34-93) 
    
Blood count parameters: Median (Range) 
  
Haemoglobin (g/L) 105.5 (38-161) 108 (53-174) 122 (84-163) 
White cell count (x10
9
/L) 13.6 (4-104.9) 10.6 (3.9-83.4) 7.9 (4.2-38.2) 
Platelets (x10
9
/L) 90 (1-442) 154 (39-1085) 150 (8-499) 
Monocytes (x10
9 ?> ? ? 2.69 (0.47-23.59) 1.71 (0.23-9.57) 1.29 (0.72-4.08) 
    
Mutation Frequency: no. of patients (%) 
  
TET2 72 (63%) 9 (32%) 31 (48%) 
SRSF2 48 (42%) 9 (32%) 14 (22%) 
ASXL1 39 (34%) 13 (46%) 10 (15%) 
NRAS 17 (15%) 7 (25%) 5 (8%) 
RUNX1 16 (14%) 6 (21%) 4 (6%) 
DNMT3A 9 (8%) 5 (18%) 5 (8%) 
CBL 18 (16%) 1 (4%) 4 (6%) 
KRAS 9 (8%) 3 (11%) 2 (3%) 
SETBP1 7 (6%) 2 (7%) 1 (2%) 
JAK2 3 (3%) 7 (25%) 1 (2%) 
EZH2 8 (7%) 2 (7%) 1 (2%) 
SF3B1 6 (5%) 2 (7%) 0 (0%) 
Abbreviations:  PB, peripheral blood;  CMML, chronic myelomonocytic leukaemia;  AML, acute myeloid leukaemia;  MPN, 
myeloproliferative neoplasm;  MDS, myelodysplastic syndrome 
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